PAHC
Fiscal year ends June Quarters are offset from the calendar — Q1 is Jul–Sep

Phibro Animal Health Corporation is a global animal health and mineral nutrition company that develops, manufactures, and markets products for food animals, including poultry, beef and dairy cattle, swine, and aquaculture. The company operates through three segments: Animal Health, which includes antibacterials, anticoccidials, nutritional specialty products, and vaccines; Mineral Nutrition, which provides dietary fortification products; and Performance Products, which supplies ingredients for personal care, industrial chemical, and chemical catalyst industries. Phibro serves livestock producers, feed manufacturers, distributors, and veterinarians across North America, Latin America, Europe, the Middle East, Africa, and Asia Pacific. Founded in 1946 as Philipp Brothers Chemicals, Inc., the company changed its name to Phibro Animal Health Corporation in 2003. Notable acquisitions include the medicated feed additive portfolio from Pfizer, the animal vaccines and adjuvants business of MVP Laboratories, and the medicated feed additive portfolio from Zoetis, completed in 2024. The company also manufactures specific ingredients for industrial applications and is expanding its companion animal product line.

Summarised from the company's own disclosures, fiscal year ended Aug 2026

Industry Specialty Chemicals Homepage pahc.com
Sector Basic Materials IR page investors.pahc.com/home/default.aspx
Tags
animal health, mineral nutrition, vaccines, antibacterials, anticoccidials, medicated feed additives, nutritional specialties, performance products, poultry, cattle, swine, aquaculture, Restoris, Rejensa, Animate, OmniGen-AF, Cellerate Yeast Solutions, KoVax, pHi-Tech Vaccination Management, Prince Agri Products, Biotay, MVP Laboratories, Osprey Biotechnics, Target Point-Technologies, ABIC Laboratories, Koffolk
Press page —

Metrics

Valuation  
Market cap $ 1.464B
Market cap (USD) $ 1.464B
P/E 14.30
PEG 0.32
P/BV 3.50
P/S 0.95
P/OCF 17.07
P/FCF 67.55
Dividend yield 1.3%
Turnover / mcap —
Returns  
ROE 29.7%
ROI 27.0%
ROIC 38.2%
Profit margin 6.6%
Growth  
Revenue growing Yes
Profits growing Yes
Revenue up 3y Yes
Revenue up 5y Yes
Earnings growth 3y (net profit CAGR) 45.2%
Quality  
Profitable Yes
Margin expanding Yes
Buying back stock No
Diluting (TTM) No
Debt/Equity 146.3%
Podcast bulls (TTM) Sign up
Podcast bears (TTM) Sign up
Podcast sentiment (TTM) Sign up
Podcast sentiment % (TTM) Sign up
News sentiment (TTM) 13
Quality score 38.9%
Insiders  
Buys, 1w Sign up
Buys, 1m Sign up
Buys, 1y Sign up
Sells, 1w Sign up
Sells, 1m Sign up
Sells, 1y Sign up

Sign up to see this company's insider trades

Figure FY 2026 FY 2025 FY 2024 FY 2023 FY 2022 FY 2021 FY 2020 FY 2019 FY 2018 FY 2017 FY 2016 FY 2015 FY 2014 FY 2013 FY 2005 FY 2004 FY 2003 FY 2002 FY 2001 FY 2000
Revenue 1.518B 1.296B 1.018B 977.889M 942.261M 833.35M 800.354M 827.995M 819.982M 764.281M 751.526M 748.591M 691.914M 653.151M 364.379M 358.274M 355.225M 388.813M 364.41M 318.056M
Net profit 99.72M 48.264M 2.416M 32.606M 49.175M 54.385M 33.552M 54.713M 64.883M 64.615M 82.728M 60.28M -3.127M 24.891M -19.665M 12.85M -17.559M -51.77M -14.895M 10.053M
Free cash flow 9.866M 41.831M 46.356M -38.484M -5.395M 18.986M 25.303M 17.278M 51.46M 77.505M 866K 48.646M -20.558M -18.51M -13.748M -3.382M 25.612M -16.091M -1.403M -30.513M

Figure FY 2026 FY 2025 FY 2024 FY 2023 FY 2022 FY 2021 FY 2020 FY 2019 FY 2018 FY 2017 FY 2016 FY 2015 FY 2014 FY 2013 FY 2005 FY 2004 FY 2003 FY 2002 FY 2001 FY 2000
Share price 31.4 25.54 16.77 13.7 19.13 28.88 26.27 31.77 46.05 37.05 18.66 38.94 21.95 — — — — — — —
Price performance 12m 0.23 0.52 0.22 -0.28 -0.34 0.1 -0.17 -0.31 0.24 0.99 -0.52 0.77 — — — — — — — —

Filed figures

Figure Jun 2017 Jun 2018 Jun 2019 Jun 2020 Jun 2021 Jun 2022 Jun 2023 Jun 2024 Jun 2025 Jun 2026
Balance sheet detail
Trade receivables (USD) 126M 136M 159M 127M 147M 167M 163M 169M 228M 239M
↳ YoY growth +1.7% +7.9% +17.2% -20.4% +16.1% +13.4% -1.8% +3.7% +34.5% +4.7%
↳ 5y CAGR +6.5% +6.9% +2.6% +3.5% +5.8% +3.8% +1.3% +12.5% +10.2%
Borrowings, current (USD) 6.25M 12.6M 12.5M 18.8M 9.38M 15M 22.3M 29.8M 16.3M —
Borrowings, non-current (USD) 242M 230M 218M 218M 297M 273M 312M 282M 615M —
Lease liabilities (USD) — — — 23.7M 34.6M 37.6M 35.1M 37.4M 42.9M 56M
Cash and deposits (USD) 56.1M 29.2M 57.6M 36.3M 50.2M 74.2M 41.3M 70.6M 68M 61.4M
Intangible assets (USD) 54.6M 52M 47.5M 71M 62.3M 63.9M 55M 45M 36.5M 30.1M
Right-of-use assets (USD) — — 0.00 22.9M 33M 37.7M 35.8M 37.6M 41.3M 51.6M
Net debt (borrowings + leases - cash) (USD) 192M 213M 173M 6.12M 291M 251M 328M 279M 607M —
Cash flow detail
Operating cash flow (USD) 98.4M 70M 47.2M 59.3M 48.3M 31.6M 13.3M 87.6M 80.1M 69M
Purchases of property, plant and equipment (USD) -20.9M -18.5M -29.9M -34M -29.3M -37M -51.8M -41.2M -38.3M -59.1M
Change in receivables (cash effect) (USD) -2.77M -11.9M -23.7M 28.7M -18.2M -23.6M 5.34M -8.68M -55.2M -7.49M
Change in inventories (cash effect) (USD) 5.43M -24.3M -21M -12.9M -12.5M -47M -11.2M 2.64M -44.3M -86.3M
Change in payables (cash effect) (USD) -3.12M 2.45M 12.1M -7.67M 3.18M 26.4M -22.8M 12M 45.6M -12.5M
Dividends paid (cash effect) (USD) -15.8M -16.1M -18.6M -19.4M -19.4M -19.4M -19.4M -19.4M -19.4M -19.5M
Interest paid (cash effect) (USD) -14.6M -11.2M -12.3M -11.6M -10.8M -11.2M -14.6M -17.3M -32.1M -42.1M
Income taxes paid (cash effect) (USD) -14.8M -15.2M -16.2M -20.9M -19.4M -17.9M -20.4M -15.4M -13.4M -20.6M
Share-based compensation (USD) 0.00 334,000 2.26M 2.26M 1.13M — — 475,000 717,000 1.6M
Operating cash flow before change in receivables (USD) 101M 81.9M 70.8M 30.6M 66.5M 55.3M 7.98M 96.3M 135M 76.4M
Free cash flow (OCF - PPE - intangibles) (USD) 77.5M 51.5M 17.3M 25.3M 19M -5.4M -38.5M 46.4M 41.8M 9.87M
Income detail
Research and development expense (USD) 9.44M 10M 12.1M 13.7M 17.8M 20.8M 24.4M 29.2M 23.7M 24.6M
↳ 5y CAGR +5.6% +8.5% +8.0% +7.6% +10.0% +17.1% +19.5% +19.3% +11.5% +6.7%
Total comprehensive income (USD) 71M 43.8M 45M -10.7M 69.5M 43.4M 39.5M -6.9M 47.8M 118M
Comprehensive income to owners (USD) 71M 43.8M 45M -10.7M 69.5M 43.4M 39.5M -6.9M 47.8M 118M
Provision for credit losses (USD) 1.41M 166,000 -201,000 230,000 105,000 255,000 943,000 1.54M 931,000 281,000
Credit cost ratio (credit losses / average receivables) (%) 1.1% 0.1% 0.1% 0.2% 0.1% 0.2% 0.6% 0.9% 0.5% 0.1%
Reported Aug 27, 2019 Aug 27, 2019 Aug 26, 2020 Nov 4, 2020 Aug 25, 2021 Nov 9, 2022 Aug 30, 2023 Aug 28, 2024 Nov 5, 2025 Aug 26, 2026

Sign up to see institutional holdings

Sign Up

Podcast Mentions

Sign up to see podcast mentions and sentiment

Sign Up

11/04/2026

TEANECK, N.J.--(BUSINESS WIRE)-- Phibro Animal Health Corporation (Nasdaq: PAHC) (“Phibro” or the “Company”) today announced financial results for its first quarter ended September 30, 2026 and maintained its financial guidance for the year ending June 30, 2027.

Highlights for the three months ended September 30, 2026 (compared to the three months ended September 30, 2025)

  • Net sales of $386.8 million, an increase of $22.9 million, or 6%
  • Net income of $29.5 million, an increase of $3.0 million, or 11%
  • Diluted income per share of $0.72, an increase of $0.07, or 11%
  • Adjusted EBITDA of $64.3 million, an increase of $2.4 million, or 4%
  • Adjusted net income of $32.4 million, an increase of $2.5 million, or 9%
  • Adjusted diluted EPS of $0.79, an increase of $0.06, or 8%

Our fiscal year 2027 Net Sales and Adjusted EBITDA guidance is as follows:

  • Net sales of $1.55 billion to $1.60 billion
  • Adjusted EBITDA of $258 million to $268 million
  • Adjusted net income of $140 million to $147 million

COMMENTARY

“We are pleased with our start to fiscal 2027,” said Dani Bendheim, President and Chief Executive Officer of Phibro Animal Health Corporation. “First quarter results exceeded our expectations and grew on top of a strong first quarter last year. The outperformance was led largely by a strong start to the year in Mineral Nutrition and Performance Products while our core Animal Health business delivered sales in line with our plan and Adjusted EBITDA ahead of plan, including the benefit of certain costs that shifted into the second quarter.”

“When we set our fiscal 2027 outlook in August, we took a disciplined approach to virginiamycin sales in Brazil. We continue to work toward the regulatory approvals necessary to make therapeutic claims for virginiamycin in Brazil, and with the election now behind us, we are optimistic that progress on those approvals may be forthcoming. Our fiscal 2027 guidance continues to assume no additional virginiamycin sales in Brazil for the remainder of the fiscal year, so any approval would represent potential upside.”

“We generated positive cash flow in the first quarter, and we see a clear opportunity to do more, particularly in managing inventory. Improving working capital and cash conversion is a top priority, and we are committed to delivering meaningful progress during fiscal 2027.”

“The first quarter was a solid start to the year. Given the timing of certain costs and the assumptions already built into our outlook, we are maintaining our fiscal 2027 financial guidance.”

QUARTERLY RESULTS

Net sales

Net sales of $386.8 million for the three months ended September 30, 2026 increased $22.9 million, or 6%, as compared to the three months ended September 30, 2025. Animal Health increased $9.6 million, Mineral Nutrition increased $10.6 million and Performance Products increased $2.7 million.

Animal Health

Net sales of $293.0 million for the three months ended September 30, 2026 increased $9.6 million, or 3%. Net sales of MFAs and other increased $11.3 million, or 6%, due to increased demand for certain of our MFAs in North America and Asia and higher sales of ethanol processing aids, partially offset by a decrease of $5.2 million in virginiamycin sales in Brazil attributable to regulatory developments in the country.

Net sales of nutritional specialty products decreased $1.1 million, or 2%, primarily due to lower poultry demand in North America and decreased aquaculture demand in South America, partially offset by higher overall demand in China and higher companion animal sales.

Net sales of vaccines decreased $0.6 million, or 2%, primarily due to lower demand for poultry products in Brazil and lower sales in Asia, partly due to timing, substantially offset by higher swine demand in North America and higher sales of adjuvant products.

Mineral Nutrition

Net sales of $73.6 million for the three months ended September 30, 2026 increased $10.6 million, or 17%, primarily due to an increase in demand and average selling prices for zinc oxide, copper and trace minerals.

Performance Products

Net sales of $20.2 million for the three months ended September 30, 2026 increased $2.7 million, or 16%, as a result of an increase in demand for copper-based and fluoride products.

Gross profit

Gross profit of $128.5 million for the three months ended September 30, 2026 increased $8.8 million, or 7%, as compared to the three months ended September 30, 2025. Gross margin increased 30 basis points to 33.2% of net sales for the three months ended September 30, 2026, as compared to 32.9% for the three months ended September 30, 2025. The comparison to the prior year includes $1.1 million for prior period acquisition-related cost of goods sold related to the purchase accounting for the acquisition of the Zoetis MFA portfolio completed in October 2024 and a net $0.1 million increase in acquisition-related depreciation expense associated with the step-up of fair value of the acquired fixed assets and intangible asset amortization. Excluding these items, gross profit increased $7.8 million, or 6%, and gross margin held flat at 34.0% of net sales. The increase in gross profit is due to increased sales volume and higher average selling prices, partially offset by higher input and distribution costs.

Excluding the items discussed above, Animal Health gross profit increased $4.6 million due to increased sales volume, partially offset by higher input and distribution costs. Mineral Nutrition gross profit increased $1.5 million, driven by higher average selling prices. Performance Products gross profit increased $1.7 million primarily as a result of higher sales and the impact of IEEPA tariff recoveries in the quarter.

Selling, general and administrative expenses

Selling, general and administrative expenses (“SG&A”) of $78.9 million for the three months ended September 30, 2026 increased $10.4 million, or 15%, as compared to the three months ended September 30, 2025. SG&A for the three months ended September 30, 2026 included $0.6 million for severance charges and other exit costs related to the planned closure of the Chicago Heights manufacturing facility and $0.4 million of performance-based stock compensation expense related to awards granted to certain named executive officers. SG&A for the three months ended September 30, 2025 included $0.3 million for acquisition-related costs and $0.2 million of performance-based stock compensation expense related to awards granted to certain named executive officers, offset by $3.8 million of insurance proceeds. Excluding these items, SG&A increased $5.9 million, or 8%.

Animal Health SG&A, excluding the non-recurring Animal Health-related items discussed above, increased $5.9 million, primarily as a result of an increase in employee-related costs. Mineral Nutrition SG&A was comparable to the prior year, and Performance Products SG&A increased $0.5 million. Corporate expense, excluding the non-recurring Corporate-related items discussed above, decreased $0.5 million due to lower consulting and business development costs, partially offset by an increase in employee related costs.

Interest expense, net

Interest expense, net of $11.3 million for the three months ended September 30, 2026 decreased by $0.8 million, as compared to the three months ended September 30, 2025, due to higher interest income attributable to interest received on IEEPA tariff recoveries and lower interest rates, partially offset by higher daily average borrowings on our revolving credit facility during the quarter.

Foreign currency (gains) losses, net

Foreign currency gains, net for the three months ended September 30, 2026, were $0.4 million, as compared to $2.9 million of net losses for the three months ended September 30, 2025. Current year gains were driven by fluctuations in certain currencies relative to the U.S. dollar, most notably in the Israeli New Shekel. Prior year losses were driven by fluctuations in certain currencies relative to the U.S. dollar, most notably in the Argentine Peso and Israeli New Shekel.

Provision for income taxes

The provision for income taxes was $9.3 million and $9.7 million for the three months ended September 30, 2026 and 2025, respectively. The effective income tax rate was 23.9% and 26.9% for the three months ended September 30, 2026 and 2025, respectively.

The effective income tax rate in the current year was higher than the federal statutory rate of 21% primarily due to the impact of state and local income taxes and the mix of foreign income, offset by tax credits.

The effective income tax rate in the current period included, among other items, foreign currency gains and certain stock-based compensation, which had lower tax rates. The effective income tax rate in the prior year included, among other items, (i) a $0.2 million expense from changes in uncertain tax positions related to prior years, (ii) $3.8 million in insurance proceeds taxed at a lower rate, and (iii) certain other charges, including acquisition transaction costs, foreign currency losses, and certain stock-based compensation, which had lower tax benefit rates. Excluding these items, the effective income tax rate was 24.5% and 25.9% for the three months ended September 30, 2026 and 2025, respectively.

It is reasonably possible we will resolve a foreign tax audit in a future quarter during this fiscal year that may have a favorable impact on our income tax rate. The Company cannot yet estimate the impact of this potential future benefit on its financial statements.

Net income

Net income of $29.5 million for the three months ended September 30, 2026 increased $3.0 million as compared to net income of $26.5 million for the three months ended September 30, 2025. Operating income decreased $1.6 million primarily due to higher SG&A partially offset by higher gross profit. Interest expense, net decreased $0.8 million due to lower interest rates and higher interest income attributable to interest received on IEEPA tariff recoveries. Foreign currency gains were $0.4 million, as compared to foreign currency net losses of $2.9 million in the prior year. Income tax expense decreased by $0.5 million.

Adjusted EBITDA

Adjusted EBITDA of $64.3 million for the three months ended September 30, 2026 increased $2.4 million, or 4%, as compared to the three months ended September 30, 2025. Animal Health Adjusted EBITDA decreased $1.0 million due to higher SG&A offsetting higher gross profit from increased sales. Mineral Nutrition Adjusted EBITDA increased $1.6 million due to higher gross profit from increased sales, and Performance Products Adjusted EBITDA increased $1.2 million due to higher sales. Corporate expenses decreased $0.6 million, driven by lower consulting and business development costs.

Adjusted provision for income taxes

The adjusted provision for income taxes was $10.5 million and $10.4 million for the three months ended September 30, 2026 and 2025, respectively. The adjusted effective income tax rates were 24.5% and 25.9% for the three months ended September 30, 2026 and 2025, respectively. The adjusted effective income tax rate for the three months ended September 30, 2026 was lower than the rate for the three months ended September 30, 2025, primarily due to the mix of income.

Adjusted net income

Adjusted net income of $32.4 million for the three months ended September 30, 2026 increased $2.5 million as compared to the prior year, primarily due to higher gross profit from sales growth, lower interest expense and a lower adjusted effective income tax rate, partially offset by higher adjusted SG&A. Adjusted SG&A increased due to higher employee-related costs.

Adjusted diluted earnings per share

Adjusted diluted earnings per share was $0.79 for the quarter, an increase of $0.06 as compared to the adjusted diluted earnings per share of $0.73 in the prior year.

BALANCE SHEET AND CASH FLOWS

  • Free cash flow was $21.7 million for the twelve months ended September 30, 2026. (Free cash flow equals cash flow from operating activities less capital expenditures.)
  • 2.9x gross leverage ratio as of September 30, 2026
    • $739.6 million total debt
    • $257.4 million Adjusted EBITDA for the twelve months ended September 30, 2026
  • Cash and short-term investments of $83.1 million as of September 30, 2026

FISCAL YEAR 2027 FINANCIAL GUIDANCE

Our fiscal year 2027 financial guidance is as shown below, with our guidance maintained from the previous quarter. Year-over-year percentages are calculated using the midpoint of the guidance ranges.

  • Net sales of $1.55 billion to $1.60 billion, 4% growth
  • Net income of $122 million to $132 million, 27% growth
  • Diluted EPS of $2.98 to $3.22, 27% growth
  • Adjusted EBITDA of $258 million to $268 million, 3% growth
  • Adjusted net income of $140 million to $147 million, 9% growth
  • Adjusted diluted EPS of $3.41 to $3.59, 9% growth
  • Adjusted effective income tax rate of ~20%

Guidance for GAAP measures assumes no additional foreign exchange (gains) losses for the year ending June 30, 2027.

WEBCAST & CONFERENCE CALL DETAILS

Phibro Animal Health Corporation will host a webcast and conference call during which the Company will review its financial results and respond to questions.

Date: Thursday, November 5, 2026
Time: 9:00 AM Eastern
Location: https://investors.pahc.com
U.S. Toll-Free: + 1 (833) 461-5787
International Toll: 1 (585) 542-9983
Conference ID: 646434646

NOTE: To join this conference call, all participants will be required to provide the Conference ID number.

A replay of the webcast will be archived and made available on Phibro’s website.

DISCLOSURE NOTICES

Forward-Looking Statements: This communication contains forward-looking statements that are subject to risks and uncertainties, including with respect to any future debt and leverage levels. All statements other than statements of historical or current fact included in this report are forward-looking statements. Forward-looking statements discuss our current expectations and projections relating to our financial condition, results of operations, plans, objectives, future performance and business. You can identify forward-looking statements by the fact that they do not relate strictly to historical or current facts. These statements may include words such as “aim,” “anticipate,” “believe,” “estimate,” “expect,” “forecast,” “outlook,” “potential,” “project,” “projection,” “plan,” “intend,” “seek,” “may,” “could,” “would,” “will,” “should,” “can,” “can have,” “likely,” the negatives thereof and other words and terms of similar meaning in connection with any discussion of the timing or nature of future operating or financial performance or other events. These statements are not guarantees of future performance or actions. If one or more of these risks or uncertainties materialize, or if management’s underlying assumptions prove to be incorrect, actual results may differ materially from those contemplated by a forward-looking statement. Forward-looking statements speak only as of the date on which they are made. Phibro expressly disclaims any obligation to update or revise any forward-looking statement, whether as a result of new information, future events or otherwise. A further list and description of risks, uncertainties and other matters can be found in our Quarterly Report on Form 10-Q and Annual Report on Form 10-K, including in the sections thereof captioned “Forward-Looking Statements” and “Risk Factors.” These filings and subsequent filings are available online at www.sec.gov , www.pahc.com , or on request from Phibro.

Non-GAAP Financial Information: We use non-GAAP financial measures, such as adjusted EBITDA, adjusted net income, adjusted diluted EPS and free cash flow to assess and analyze our operational results and trends and to make financial and operational decisions. Management uses adjusted EBITDA as its primary operating measure. We report adjusted net income to portray the results of our operations prior to considering certain income statement elements. We believe these non-GAAP financial measures are also useful to investors because they provide greater transparency regarding our operating performance. The non-GAAP financial measures included in this communication should not be considered alternatives to measurements required by GAAP, such as net income, operating income and earnings per share, and should not be considered measures of liquidity. These non-GAAP financial measures may not be comparable with non-GAAP information provided by other companies. Reconciliation of non-GAAP financial measures and GAAP financial measures are included in the tables accompanying this communication and/or our Quarterly Report on Form 10-Q and Annual Report on Form 10-K.

We are not providing a reconciliation of forward-looking guidance of non-GAAP financial measures to the most directly comparable GAAP financial measures because of the uncertainty regarding, and the potential variability of, certain of the items required for a reconciliation; accordingly, a reconciliation of the non-GAAP financial measure to the corresponding GAAP financial measure is not available without unreasonable effort. These items are uncertain, depend on various factors and may have a material impact on our future GAAP results.

Internet Posting of Information: We routinely post information that may be important to investors in the “Investors” section of our website at www.pahc.com . We encourage investors and potential investors to consult our website regularly for important information about us.

Phibro Animal Health Corporation
Consolidated Results of Operations
Three Months
For the Periods Ended September 30 2026 2025 Change
(in millions, except per share amounts and percentages)
Net sales $ 386.8 $ 363.9 $ 22.9 6 %
Cost of goods sold 258.2 244.1 14.1 6 %
Gross profit 128.5 119.8 8.8 7 %
Selling, general and administrative expenses 78.9 68.5 10.4 15 %
Operating income 49.6 51.3 (1.6) (3) %
Interest expense, net 11.3 12.1 (0.8) (6) %
Foreign currency (gains) losses, net (0.4) 2.9 (3.4) *
Income before income taxes 38.8 36.3 2.5 7 %
Provision for income taxes 9.3 9.7 (0.5) (5) %
Net income $ 29.5 $ 26.5 $ 3.0 11 %
Net income per share
basic $ 0.73 $ 0.65 $ 0.08 12 %
diluted $ 0.72 $ 0.65 $ 0.07 11 %
Weighted average common shares outstanding
basic 40.6 40.5
diluted 41.0 40.9
Ratio to net sales
Gross profit 33.2 % 32.9 %
Selling, general and administrative expenses 20.4 % 18.8 %
Operating income 12.8 % 14.1 %
Income before income taxes 10.0 % 10.0 %
Net income 7.6 % 7.3 %
Effective tax rate 23.9 % 26.9 %
Amounts and percentages may reflect rounding adjustments.
* Calculation not meaningful
Phibro Animal Health Corporation
Segment Net Sales and Adjusted EBITDA
Three Months
For the Periods Ended September 30 2026 2025 Change
(in millions, except percentages)
Net Sales
MFAs and other $ 206.5 $ 195.2 $ 11.3 6 %
Nutritional specialties 47.1 48.2 (1.1) (2) %
Vaccines 39.5 40.1 (0.6) (2) %
Animal Health 293.0 283.5 9.6 3 %
Mineral Nutrition 73.6 63.0 10.6 17 %
Performance Products 20.2 17.4 2.7 16 %
Total $ 386.8 $ 363.9 $ 22.9 6 %
Adjusted EBITDA
Animal Health $ 73.9 $ 74.9 $ (1.0) (1) %
Mineral Nutrition 6.2 4.5 1.6 36 %
Performance Products 2.8 1.6 1.2 75 %
Corporate (18.6) (19.1) 0.6 (3) %
Total $ 64.3 $ 61.9 $ 2.4 4 %
Ratio to segment net sales
Animal Health 25.2 % 26.4 %
Mineral Nutrition 8.4 % 7.2 %
Performance Products 13.9 % 9.2 %
Corporate(1) (4.8) % (5.3) %
Total(1) 16.6 % 17.0 %
Reconciliation of GAAP Net Income to Adjusted EBITDA
Net income $ 29.5 $ 26.5 $ 3.0 11 %
Interest expense, net 11.3 12.1 (0.8) (6) %
Provision for income taxes 9.3 9.7 (0.5) (5) %
Depreciation and amortization 13.6 12.8 0.7 6 %
EBITDA 63.6 61.2 2.5 4 %
Restructuring charges - SG&A(2) 0.6 — 0.6 *
Acquisition-related cost of goods sold — 1.1 (1.1) *
Acquisition-related transaction costs — 0.3 (0.3) *
Phibro Forward income growth initiatives - SG&A 0.0 ** — 0.0 *
Stock-based compensation expense - named executive officer performance awards 0.4 0.2 0.2 *
Insurance settlement 0.0 ** (3.8) 3.8 *
Foreign currency (gains) losses, net (0.4) 2.9 (3.4) *
Adjusted EBITDA $ 64.3 $ 61.9 $ 2.4 4 %
Amounts and percentages may reflect rounding adjustments.
* Calculation not meaningful
** Amount less than $0.1 million
(1) Reflects ratio to total net sales
(2) Restructuring charges recorded in SG&A include severance charges and other exit costs related to the planned closure of our manufacturing facility in Chicago Heights, Illinois.
Phibro Animal Health Corporation
Adjusted Net Income
Three Months
For the Periods Ended September 30 2026 2025 Change
(in millions, except per share amounts and percentages)
Reconciliation of GAAP Net Income to Adjusted Net Income
Net income $ 29.5 $ 26.5 $ 3.0 11 %
Acquisition-related depreciation(1) 1.7 1.6 0.1 8 %
Acquisition-related intangible amortization(1) 1.1 1.1 0.0 1 %
Acquisition-related intangible amortization(2) 0.6 0.6 0.0 2 %
Acquisition-related cost of goods sold(1) — 1.1 (1.1) *
Acquisition-related transaction costs(2) — 0.3 (0.3) *
Restructuring charges - SG&A(2)(3) 0.6 — 0.6 *
Insurance proceeds(2) 0.0 ** (3.8) 3.8 *
Stock-based compensation expense - named executive officer performance awards 0.4 0.2 0.2 *
Phibro Forward income growth initiatives - SG&A(2) 0.0 ** — 0.0 *
Foreign currency (gains) losses, net(4) (0.4) 2.9 (3.4) *
Adjustments to income taxes(5) (1.2) (0.7) 0.5 (78) %
Adjusted net income $ 32.4 $ 29.8 $ 2.5 9 %
Statement of Operations Line Items - adjusted
Adjusted cost of goods sold(1) $ 255.4 $ 240.3 $ 15.1 6 %
Adjusted gross profit 131.4 123.6 7.8 6 %
Adjusted selling, general and administrative(2) 77.2 71.3 5.9 8 %
Interest expense, net 11.3 12.1 (0.8) (6) %
Adjusted income before income taxes 42.9 40.3 2.6 6 %
Adjusted provision for income taxes(5) 10.5 10.4 0.1 1 %
Adjusted net income $ 32.4 $ 29.8 $ 2.5 9 %
Adjusted net income per share
diluted $ 0.79 $ 0.73 $ 0.06 8 %
Weighted average common shares outstanding
diluted 41.0 40.9
Ratio to net sales
Adjusted gross profit 34.0 % 34.0 %
Adjusted selling, general and administrative(2) 20.0 % 19.6 %
Adjusted income before income taxes 11.1 % 11.1 %
Adjusted net income 8.4 % 8.2 %
Adjusted effective tax rate 24.5 % 25.9 %
Amounts and percentages may reflect rounding adjustments.
* Calculation not meaningful
** Amount less than $0.1 million
(1) Adjusted cost of goods sold excludes acquisition-related depreciation associated with the step-up of fair value of the acquired fixed assets, acquisition-related intangible amortization and acquisition-related cost of goods sold.
(2) Adjusted selling, general and administrative excludes restructuring-related severance charges and other exit costs related to the planned closure of our manufacturing facility in Chicago Heights, Illinois, acquisition-related intangible amortization, acquisition-related transaction costs, stock-based compensation related to performance awards granted to certain named executive officers, costs associated with Phibro Forward income growth initiatives, and insurance proceeds.
(3) Restructuring charges recorded in SG&A include severance charges and other exit costs related to the planned closure of our manufacturing facility in Chicago Heights, Illinois.
(4) Foreign currency (gains) losses, net, are excluded from adjusted net income.
(5) Adjusted provision for income taxes excludes the income tax effect of pre-tax income adjustments.

About Phibro Animal Health Corporation

Phibro Animal Health Corporation is a leading global diversified animal health and mineral nutrition company. We strive to be a trusted partner with livestock producers, farmers, veterinarians and consumers who raise or care for farm and companion animals by providing solutions to help them maintain and enhance the health of their animals. For further information, please visit www.pahc.com .

Phibro Animal Health Corporation
Patrick Rodriguez
Vice President, Finance, Treasurer and Head of Investor Relations
+1-201-329-7300
Or
[email protected]

Source: Phibro Animal Health Corporation

Multimedia Files:

View All News

Phibro Corporation Logo

Phibro Animal Health Corporation

Glenpointe Centre East, 3rd Fl
300 Frank W. Burr Blvd., Ste 21
Teaneck, NJ 07666-6712
USA

Quick Links

Investor Alerts

To opt-in for investor email alerts, please enter your email address in the field below and select at least one alert option. After submitting your request, you will receive an activation email to the requested email address. You must click the activation link in order to complete your subscription. You can sign up for additional alert options at any time.

At Phibro Animal Health Corporation, we promise to treat your data with respect and will not share your information with any third party. You can unsubscribe to any of the investor alerts you are subscribed to by visiting the ‘unsubscribe’ section below. If you experience any issues with this process, please contact us for further assistance.

By providing your email address below, you are providing consent to Phibro Animal Health Corporation to send you the requested Investor Email Alert updates.

* Required

Email Address * Mailing Lists *

Press Releases
Events
Presentations
SEC Filings
End of Day Stock Quote
Quarterly & Annual Reports

Unsubscribe

© 2009 - 2026 Phibro Animal Health Corporation. All rights reserved.
Privacy Policy

Powered By Q4 Inc. 5.191.0.1 (opens in new window)

Cookie Settings

Phibro Animal Health Corporation Declares Quarterly Dividend Bull 0 Bear 0 Capital return

11/03/2026

TEANECK, N.J.--(BUSINESS WIRE)-- The Board of Directors of Phibro Animal Health Corporation (Nasdaq: PAHC) today declared a quarterly cash dividend of $0.12 per share on its Class A common stock and Class B common stock, payable on December 16, 2026, to stockholders of record at the close of business on November 25, 2026.

About Phibro Animal Health Corporation

Phibro Animal Health Corporation is a leading global diversified animal health and nutrition company. We strive to be a trusted partner with livestock producers, farmers, veterinarians and consumers who raise or care for farm and companion animals by providing solutions to help them maintain and enhance the health of their animals. For further information, please visit www.pahc.com .

Phibro Animal Health Corporation
Glenn David
Chief Financial Officer
+1-201-329-7300
Or
[email protected]

Source: Phibro Animal Health Corporation

Multimedia Files:

View All News

Phibro Corporation Logo

Phibro Animal Health Corporation

Glenpointe Centre East, 3rd Fl
300 Frank W. Burr Blvd., Ste 21
Teaneck, NJ 07666-6712
USA

Quick Links

Investor Alerts

To opt-in for investor email alerts, please enter your email address in the field below and select at least one alert option. After submitting your request, you will receive an activation email to the requested email address. You must click the activation link in order to complete your subscription. You can sign up for additional alert options at any time.

At Phibro Animal Health Corporation, we promise to treat your data with respect and will not share your information with any third party. You can unsubscribe to any of the investor alerts you are subscribed to by visiting the ‘unsubscribe’ section below. If you experience any issues with this process, please contact us for further assistance.

By providing your email address below, you are providing consent to Phibro Animal Health Corporation to send you the requested Investor Email Alert updates.

* Required

Email Address * Mailing Lists *

Press Releases
Events
Presentations
SEC Filings
End of Day Stock Quote
Quarterly & Annual Reports

Unsubscribe

© 2009 - 2026 Phibro Animal Health Corporation. All rights reserved.
Privacy Policy

Powered By Q4 Inc. 5.191.0.1 (opens in new window)

Cookie Settings

10/28/2026

TEANECK, N.J.--(BUSINESS WIRE)-- Phibro Animal Health Corporation (Nasdaq: PAHC) expects to announce its first quarter financial results on Wednesday, November 4, 2026, after the market closes. Phibro management will host a conference call and webcast on Thursday, November 5, 2026, at 9:00 AM Eastern Time.

Interested parties are invited to listen to the conference call and view the presentation slides by visiting https://investors.pahc.com. The discussion will also be available by dialing +1 (833) 461-5787 in the U.S. or +1 (585) 542-9983 for international callers. Provide the conference ID 646434646.

A replay of the webcast will be available approximately two hours after the conclusion of the live event. To access the webcast recording, visit https://investors.pahc.com.

About Phibro Animal Health Corporation

Phibro Animal Health Corporation is a leading global diversified animal health and mineral nutrition company. We strive to be a trusted partner with livestock producers, farmers, veterinarians, and consumers who raise or care for farm and companion animals by providing solutions to help them maintain and enhance the health of their animals. For further information, please visit www.pahc.com .

Our filings with the Securities and Exchange Commission are available online at www.sec.gov, www.pahc.com or on request from the company.

Glenn C. David
Chief Financial Officer, Phibro Animal Health Corporation
+1-201-329-7300
[email protected]

Source: Phibro Animal Health Corporation

Multimedia Files:

View All News

Phibro Corporation Logo

Phibro Animal Health Corporation

Glenpointe Centre East, 3rd Fl
300 Frank W. Burr Blvd., Ste 21
Teaneck, NJ 07666-6712
USA

Quick Links

Investor Alerts

To opt-in for investor email alerts, please enter your email address in the field below and select at least one alert option. After submitting your request, you will receive an activation email to the requested email address. You must click the activation link in order to complete your subscription. You can sign up for additional alert options at any time.

At Phibro Animal Health Corporation, we promise to treat your data with respect and will not share your information with any third party. You can unsubscribe to any of the investor alerts you are subscribed to by visiting the ‘unsubscribe’ section below. If you experience any issues with this process, please contact us for further assistance.

By providing your email address below, you are providing consent to Phibro Animal Health Corporation to send you the requested Investor Email Alert updates.

* Required

Email Address * Mailing Lists *

Press Releases
Events
Presentations
SEC Filings
End of Day Stock Quote
Quarterly & Annual Reports

Unsubscribe

© 2009 - 2026 Phibro Animal Health Corporation. All rights reserved.
Privacy Policy

Powered By Q4 Inc. 5.190.1.9 (opens in new window)

Cookie Settings

Prompts

Phibro Animal Health Corporation (ticker PAHC), listed in United States.

Company History

Date Change Detail
Sep 12, 2003 Renamed PHILIPP BROTHERS CHEMICALS INC → PHIBRO ANIMAL HEALTH CORP

ETFs Holding Phibro Animal Health Corporation

ETF Weight in ETF Shares Market value As of
SMIZ 0.52% 38,008 $ 1.434M Aug 31, 2026
LITL 0.48% 791 $ 27.622K Nov 17, 2026
SYZ 0.29% 6,400 $ 200.96K Jun 30, 2026
SQLV 0.21% 1,947 $ 61.136K Jun 30, 2026
SAGP 0.20% 4,790 $ 150.406K Jun 30, 2026
OASC 0.18% 4,376 $ 165.15K Aug 31, 2026
RUSC 0.14% 3,640 $ 114.296K Jun 30, 2026
SEIS 0.14% 26,530 $ 833.042K Jun 30, 2026
JMEE 0.07% 60,156 $ 2.101M Nov 17, 2026
FESM 0.05% 91,369 $ 2.869M Jun 30, 2026
SMDX 0.04% 1,415 $ 49.553K Nov 17, 2026
PSC 0.03% 23,282 $ 731.055K Jun 30, 2026
RESM 0.03% 36 $ 1,130.40 Jun 30, 2026
AVSC 0.03% 26,495 $ 927.855K Nov 16, 2026
EBI 0.03% 4,967 $ 187.455K Aug 31, 2026
DFAS 0.02% 157,964 $ 5.601M Nov 12, 2026
AVUQ 0.01% 698 $ 24.444K Nov 16, 2026
DXUV 0.01% 13,441 $ 476.618K Nov 12, 2026
DFAC 0.00% 93,054 $ 3.3M Nov 12, 2026
MSSM 0.00% 702 $ 26.493K Aug 31, 2026
DCOR 0.00% 34,355 $ 1.218M Nov 12, 2026
DFAU 0.00% 5,404 $ 191.626K Nov 12, 2026
DFUS 0.00% 6,889 $ 244.284K Nov 12, 2026
DFUV 0.00% 1,703 $ 60.388K Nov 12, 2026
DFAT 0.00% 274 $ 9,716.04 Nov 12, 2026
AVUS 0.00% 8,057 $ 282.156K Nov 16, 2026